Personalized Medicine in Cardio-Oncology
A special issue of Journal of Personalized Medicine (ISSN 2075-4426).
Deadline for manuscript submissions: closed (15 July 2022) | Viewed by 4156
Special Issue Editors
Interests: microenvironment; chemokines; chemoresistance; inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Several therapies have significantly increased the survival of cancer patients; however, a high risk of adverse cardiac outcomes, such as heart failure (HF) and cardiomyopathy (CM), has also been observed. Innovative anticancer therapies, such as PARP inhibitors, immune check-point inhibitors, CDK-4/6 inhibitors, and new HER-2 blocking agents, available in clinical trials and then integrated in clinical practice, have also shown cardiotoxicity effects, such as abnormalities in left ventricular function, leading to HF or CM, vasculotoxicity and metabolic diseases. The risk of severe cardiotoxicity could be higher in cancer patients already treated with standard chemotherapies, such as anthracyclines, affecting the therapeutical choices of clinicians. This Special Issue welcomes systematic reviews and communications, as well as original research, in the fields of target therapy, vasculo-toxicity, interdisciplinary health research, preclinical models, translational and clinical research, and epidemiologic research, covering the above cardio-oncology topics.
Prof. Dr. Vincenzo Quagliariello
Dr. Stefania Cocco
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- target therapy
- cardio-oncology
- cancer
- inflammation
- immunotherapy
- cardio-protection
- translation research